GSK plc (GSK)

NYSE: GSK · Real-Time Price · USD
46.86
-0.08 (-0.17%)
At close: Oct 31, 2025, 4:00 PM EDT
45.90
-0.96 (-2.05%)
After-hours: Oct 31, 2025, 4:44 PM EDT
-0.17%
Market Cap94.19B
Revenue (ttm)43.24B
Net Income (ttm)7.39B
Shares Out 3.74B
EPS (ttm)1.79
PE Ratio26.24
Forward PE10.40
Dividend$1.62 (3.46%)
Ex-Dividend DateAug 15, 2025
Volume5,022,815
Open46.85
Previous Close46.94
Day's Range46.57 - 47.12
52-Week Range31.72 - 47.16
Betan/a
AnalystsBuy
Price Targetn/a
Earnings DateOct 29, 2025

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]

Sector Healthcare
Founded 1715
Employees 68,629
Stock Exchange NYSE
Ticker Symbol GSK
Full Company Profile

Financial Performance

In 2024, GSK's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial numbers in GBP Financial Statements

News

GSK plc (GSK) Q3 2025 Earnings Call Transcript

GSK plc ( GSK) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Emma Walmsley - CEO & Director Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO of ViiV Healthcare...

2 days ago - Seeking Alpha

GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported upbeat third-quarter results and upgraded its full-year 2025 guidance.

2 days ago - Benzinga

GSK Raises Guidance After Sales, Earnings Growth

The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.

2 days ago - WSJ

GSK raises 2025 sales forecast after strong growth in specialty medicines

GSK raised its 2025 sales expectations on Wednesday after third-quarter results beat expectations, driven by double-digit growth in its specialty medicines, including HIV and oncology.

2 days ago - Reuters

GSK shares fall as narrow approval of blood cancer drug limits US relaunch

GSK's London-listed shares fell nearly 2% on Friday after the U.S. Food and Drug Administration approved only one of two treatment combinations with the British firm's blood cancer drug, limiting the ...

7 days ago - Reuters

FTSE 100 Index shares to watch: HSBC, Standard Chartered, Haleon, GSK

The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings and macro data. It has jumped by over 27% from its lowest level this year.

Other symbols: HLN
7 days ago - Invezz

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

PHILADELPHIA--(BUSINESS WIRE)-- #BelantamabMafodotin--Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma.

7 days ago - Business Wire

US FDA approve GSK's blood cancer treatment

The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in combination with other treatments, the company said on Thursday, paving the way for a relaunch...

8 days ago - Reuters

UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug

The UK's drugs cost-effectiveness watchdog has given a positive recommendation for ViiV Healthcare's HIV drug, enabling access to the preventive medicine via the state health system in England and Wal...

14 days ago - Reuters

GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon

GSK plc aka GlaxoSmithKline is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved market ...

21 days ago - Seeking Alpha

GSK's Hidden Growth Engines Beyond HIV And Oncology

GSK continues to successfully develop its oncology franchise. So, sales of its "gem" in the treatment of myelofibrosis, called Ojjaara, reached $183 million in the second quarter of 2025, increasing b...

22 days ago - Seeking Alpha

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

25 days ago - Seeking Alpha

Focus: US Health Secretary Kennedy speeds autism drug with GSK help

U.S. Health Secretary Robert F Kennedy Jr. could deliver a policy win for the Trump administration in just a few months after the Food and Drug Administration enlisted GSK to help it fast-track approv...

25 days ago - Reuters

New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level

PHILADELPHIA--(BUSINESS WIRE)-- #AdultVaccination--GSK plc (LSE/NYSE: GSK) today announced a major update to Vaccine Track, a first-of-its-kind, interactive public data tool for tracking adult immuniz...

4 weeks ago - Business Wire

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Other symbols: BMYXRAY
4 weeks ago - Benzinga

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026.

4 weeks ago - Benzinga

GSK turns to insider to be next CEO — and the stock rallies

Shares of U.K. pharmaceutical giant GSK rallied on Monday after it turned to an insider to become its next CEO.

4 weeks ago - Market Watch

Who is GSK's next CEO Luke Miels?

British drugmaker GSK named insider Luke Miels as its CEO designate on Monday to succeed Emma Walmsley, who will step down after nine years in the role.

4 weeks ago - Reuters

GSK names Luke Miels as next CEO after Emma Walmsley steps down; shares jump

GSK announced on Monday that Chief Executive Emma Walmsley will step down after nine years in the role, with current Chief Commercial Officer Luke Miels set to take over on January 1. The transition m...

4 weeks ago - Invezz

GSK names Luke Miels as CEO designate

British drugmaker GSK said on Monday it has appointed Luke Miels as CEO designate and he will assume full responsibilities as chief executive on January 1, 2026.

4 weeks ago - Reuters

GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript

GSK plc (NYSE:GSK) plc Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDT Company Participants Julie Brown - CFO & Executive Director Tony Wood - Chief Scientific Office...

5 weeks ago - Seeking Alpha

Pi Health to Collaborate with GSK to Enhance Clinical Research Services

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pi Health, a global health technology and clinical research company, today announced it will provide fully outsourced clinical research services in a GSK clinical tr...

5 weeks ago - Business Wire

GSK to submit label update for Leucovorin at FDA's request, does not intend to market it for autism

CNBC's Angelica Peebles joins 'Fast Money' with breaking news on GSK and its drug Leucovorin.

5 weeks ago - CNBC Television

FDA approves drug that Trump due to suggest as autism treatment

The U.S. Food and Drug Administration announced approval of leucovorin, a form of folic acid that U.S. President Donald Trump was slated to suggest as a treatment for autism symptoms at a White House ...

5 weeks ago - Reuters

UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit

British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.

6 weeks ago - CNBC